There were no differences in OS and disease-free survival across the different codon 12 mutations.[4] Aredo et al[28] included 186 NSCLC patients with KRAS mutations in stages I to IV and found that KRAS G12D mutations were associated with poor OS, as were STK11 co-mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.